# US 2021/0078993 A1 · A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0078993 A1
- Document ID: US20210078993A1
- Status: Published application
- Kind: A1
- Application number: 16/771,799
- Filed: 2018-12-26
- Published: 2021-03-18
- Earliest claimed: 2017-12-26
- Assignees: Crystal Pharmaceutical (Suzhou) Co., Ltd.
- Applicants: Crystal Pharmaceutical (Suzhou) Co., Ltd.
- Inventors: Minhua Chen; Yanfeng Zhang; Chaohui Yang; Chunxiang Huang
- Web page: https://patentgrep.com/patent/US20210078993A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61P 25/00: Drugs for disorders of the nervous system
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

A crystalline form of valbenazine ditosylate, processes for preparation thereof, a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing vesicular monoamine transporter 2 inhibitor drugs, and use of the crystalline form for preparing drugs treating tardive dyskinesia.

## Claims

### Claim 1

A valbenazine ditosylate crystalline form A,
wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 5.9°±0.2°, 13.3°±0.2° and 19.8°±0.2° using CuKα radiation.

### Claim 2 (depends on 1)

The valbenazine ditosylate crystalline form A according to claim 1, wherein the X-ray powder diffraction pattern shows one or two or three characteristic peaks at 2theta values of 11.0°±0.2°, 8.7°±0.2° and 15.8°±0.2° using CuKα radiation.

### Claim 3 (depends on 1)

A process for preparing the valbenazine ditosylate crystalline form A according to claim 1, wherein the process comprises: adding a valbenazine ditosylate solvate into an ether, stirring at −20° C.-25° C., filtering the solid, and drying to obtain the crystalline form A.

### Claim 4 (depends on 3)

The process for preparing the valbenazine ditosylate crystalline form A according to claim 3, wherein said valbenazine ditosylate solvate is a 2-MeTHF and water co-solvate, said ether is anisole.

### Claim 5 (depends on 4)

The process for preparing the valbenazine ditosylate crystalline form A according to claim 4, wherein said 2-MeTHF and water co-solvate is a crystalline form, the X-ray powder diffraction pattern is substantially as depicted in FIG. 1 using CuKα radiation.

### Claim 6 (depends on 1)

A pharmaceutical composition, said pharmaceutical composition comprises a therapeutically effective amount of the valbenazine ditosylate crystalline form A according to claim 1, and pharmaceutically acceptable carriers, diluents or excipients.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A method of treating tardive dyskinesia, comprising administering to a subject in need thereof a therapeutically effective amount of the valbenazine ditosylate crystalline form A according to claim 1.
